Meeting
2020 ASCO Virtual Scientific Program
Surgery for unresectable stage IIIC and IV melanoma in the era of new systemic therapy.
Authors
Stephanie Blankenstein
Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
Stephanie Blankenstein , Maureen J.B. Aarts , Franchette van den Berkmortel , Marye Boers-Sonderen , Alfonsus Johannes Maria van den Eertwegh , Margreet G. Franken , Jan Willem de Groot , John B. A. G. Haanen , Geke Hospers , Ellen Kapiteijn , Djura Piersma , Rozemarijn Van Rijn , Karijn Suijkerbuijk , Albert J. ten Tije , Astrid Aplonia Maria Van Der Veldt , Gerard Vreugdenhil , Michel W.J.M. Wouters , Alexander Christopher Jonathan Van Akkooi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 38: 2020 (suppl; abstr 10032)
DOI
10.1200/JCO.2020.38.15_suppl.10032
Abstract #
10032
Poster Bd #
381
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Impact of systemic therapy sequencing on overall survival for patients with advanced BRAF-mutated melanoma.
First Author: B. Adi Kartolo
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Prognostic value of the timing of immune checkpoint inhibitors infusion in patients with advanced hepatocellular carcinoma.
First Author: Alina Pascale
Poster
2023 ASCO Annual Meeting
Intralesional therapy, limb infusion/perfusion, and immune checkpoint inhibitors as first-line therapy in surgically unresectable melanoma in-transit metastases.
First Author: Danielle K DePalo
Poster
2023 ASCO Annual Meeting
Association of ultra-sensitive ctDNA assay to identify actionable variants and response to immune checkpoint inhibitor (ICI) therapy in metastatic melanoma.
First Author: Christoffer Gebhardt